Vaneltix announces the results of the 2020 Stockholder Offering and Bridge Loan Conversion: The company raised additional proceeds of $900,000 and all the Bridge Loans were converted into Common Stock at their respective conversion prices. All the conversions and purchases were eligible to apply for the Angel Investor NJ Tax Credit, and as a result of the 2020 Securities Modification and the Stockholder Offering, the Company is for the first time mainly debt free and the Company has no liens nor encumbrances on its assets.
Vaneltix planning to enroll subjects in new round of clinical trials
On Tuesday, February 21st 2023, Bound Brook, NJ – Vaneltix Pharma, Inc. (Formerly Urigen Pharmaceuticals, Inc.; “Vaneltix” or “the Company”), a specialty pharmaceutical company focused
February 21, 2023
